AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill F LT 3-ITD acute myeloid leukemia

FMS-like Tyrosine Kinase 3 (FLT3) mutation is associated with poor survival in acute myeloid leukemia (AML). The specific Anexelekto/MER Tyrosine Kinase (AXL) inhibitor, ONO-7475, kills FLT3-mutant AML cells with targets including Extracellular-signal Regulated Kinase (ERK) and Myeloid Cell Leukemia...

Descripción completa

Detalles Bibliográficos
Autores principales: Post, Sean M., Ma, Huaxian, Malaney, Prerna, Zhang, Xiaorui, Aitken, Marisa J.L., Mak, Po Yee, Ruvolo, Vivian R., Yasuhiro, Tomoko, Kozaki, Ryohei, Chan, Lauren E., Ostermann, Lauren B., Konopleva, Marina, Carter, Bing Z., DiNardo, Courtney, Andreeff, Michael D., Khoury, Joseph D., Ruvolo, Peter P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2021
Materias:
Article - Acute Myeloid Leukemia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9152975/
https://www.ncbi.nlm.nih.gov/pubmed/34732043
http://dx.doi.org/10.3324/haematol.2021.278369

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9152975/
https://www.ncbi.nlm.nih.gov/pubmed/34732043
http://dx.doi.org/10.3324/haematol.2021.278369

Ejemplares similares